- Home
- ALLO vs PRQR Comparison
ALLO vs PRQR Comparison
Compare ALLO & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLO
- PRQR
- Stock Information
- Founded
- ALLO 2017
- PRQR 2012
- Country
- ALLO United States
- PRQR Netherlands
- Employees
- ALLO N/A
- PRQR N/A
- Industry
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- ALLO Health Care
- PRQR Health Care
- Exchange
- ALLO Nasdaq
- PRQR Nasdaq
- Market Cap
- ALLO 371.8M
- PRQR 309.5M
- IPO Year
- ALLO 2018
- PRQR 2014
- Fundamental
- Price
- ALLO $1.11
- PRQR $1.72
- Analyst Decision
- ALLO Strong Buy
- PRQR Strong Buy
- Analyst Count
- ALLO 10
- PRQR 7
- Target Price
- ALLO $8.90
- PRQR $9.00
- AVG Volume (30 Days)
- ALLO 4.1M
- PRQR 573.8K
- Earning Date
- ALLO 05-13-2025
- PRQR 05-08-2025
- Dividend Yield
- ALLO N/A
- PRQR N/A
- EPS Growth
- ALLO N/A
- PRQR N/A
- EPS
- ALLO N/A
- PRQR N/A
- Revenue
- ALLO N/A
- PRQR $21,212,711.00
- Revenue This Year
- ALLO N/A
- PRQR $2.87
- Revenue Next Year
- ALLO $9.07
- PRQR N/A
- P/E Ratio
- ALLO N/A
- PRQR N/A
- Revenue Growth
- ALLO N/A
- PRQR 85.91
- 52 Week Low
- ALLO $0.86
- PRQR $1.07
- 52 Week High
- ALLO $3.78
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- ALLO 38.30
- PRQR 57.21
- Support Level
- ALLO $1.07
- PRQR $1.47
- Resistance Level
- ALLO $1.15
- PRQR $1.70
- Average True Range (ATR)
- ALLO 0.14
- PRQR 0.15
- MACD
- ALLO -0.01
- PRQR 0.01
- Stochastic Oscillator
- ALLO 27.17
- PRQR 45.87
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.